Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

1.3K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.3K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

1.2K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.2K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

961
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
961
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

3.1K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
3.1K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

6.1K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
6.1K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Gad et al. Management of Childhood Obesity. <i>Int. J. Mol. Sci.</i> 2026, <i>27</i>, 3528.

International journal of molecular sciences·2026
Same author

Case Report: Effect of setmelanotide treatment in a young patient with acquired hypothalamic obesity following <i>Escherichia coli</i> sepsis and meningoencephalitis with brain abscess.

Frontiers in endocrinology·2026
Same author

Effect of dual hepatic and portal vein embolization on future liver remnant function and volume prior to major hepatectomy.

Annals of hepato-biliary-pancreatic surgery·2026
Same author

Distal ureterectomy versus radical nephroureterectomy for nonmetastatic distal ureteral urothelial carcinoma: a GRADE-assessed systematic review and meta-analysis of comparative studies.

World journal of surgical oncology·2026
Same author

Zaleya pentandra L. produces anti-arthritic effects by downregulating IL-6, NF-κB, and TNF-α and mitigating oxidative stress.

Inflammopharmacology·2026
Same author

Ethnobotanical survey of medicinal plants traditionally used in Daulat Nagar, Punjab, Pakistan.

Journal of ethnobiology and ethnomedicine·2026

Related Experiment Video

Updated: Apr 6, 2026

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

96.2K

Hyperinsulinemic Hypoglycemia.

Maria Güemes1, Khalid Hussain1

  • 1Developmental Endocrinology Research Group, Molecular Genetics Unit, Institute of Child Health, University College London, 30 Guilford Street, London WC1N 1EH, UK.

Pediatric Clinics of North America
|July 27, 2015
PubMed
Summary

Hyperinsulinemic hypoglycemia (HH) involves abnormal insulin secretion, causing dangerous low blood glucose. Prompt diagnosis and management are crucial to prevent brain injury in newborns.

Keywords:
18F-l-dihydroxyphenylalanine positron emission tomographic scanDiazoxideHyperinsulinismHypoglycemiaMammalian target of rapamycin (mTOR) inhibitorOctreotidePancreatectomy

More Related Videos

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.5K
Author Spotlight: Investigating the Blood Glucose Homeostasis in Murine Brain Using a Cost-Effective Hyperglycemic And Hypoglycemic Clamp Technique
07:35

Author Spotlight: Investigating the Blood Glucose Homeostasis in Murine Brain Using a Cost-Effective Hyperglycemic And Hypoglycemic Clamp Technique

Published on: January 26, 2024

2.4K

Related Experiment Videos

Last Updated: Apr 6, 2026

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

96.2K
Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.5K
Author Spotlight: Investigating the Blood Glucose Homeostasis in Murine Brain Using a Cost-Effective Hyperglycemic And Hypoglycemic Clamp Technique
07:35

Author Spotlight: Investigating the Blood Glucose Homeostasis in Murine Brain Using a Cost-Effective Hyperglycemic And Hypoglycemic Clamp Technique

Published on: January 26, 2024

2.4K

Area of Science:

  • Endocrinology
  • Neonatal Medicine
  • Metabolic Disorders

Background:

  • Hyperinsulinemic hypoglycemia (HH) is characterized by dysregulated insulin secretion from pancreatic beta-cells, leading to blood glucose levels inappropriate for prevailing glycemia.
  • This condition poses a significant risk of brain injury in newborns due to insulin's suppression of lipolysis and ketogenesis, hindering alternative brain fuel production.

Purpose of the Study:

  • To review the physiological mechanisms of glucose regulation in newborns.
  • To elucidate the intricate mechanisms governing insulin secretion.
  • To categorize the various etiologic types of hyperinsulinemic hypoglycemia and outline current management strategies.

Main Methods:

  • Literature review of glucose physiology in neonates.
  • Analysis of insulin secretion pathways.
  • Synthesis of information on HH etiology and treatment.

Main Results:

  • Dysregulated insulin secretion in HH leads to severe hypoglycemia.
  • Inhibition of lipolysis and ketogenesis by insulin prevents ketone body formation, a critical alternative energy source for the brain.
  • Early diagnosis and appropriate management are vital for preventing neurological damage.

Conclusions:

  • Understanding glucose homeostasis and insulin secretion is key to recognizing HH.
  • Prompt diagnosis and effective management of HH are essential to mitigate the risk of brain injury in affected infants.